Lunit was in the news earlier in January when its INSIGHT AI – a deep learning-based technology for evaluating diagnostic images – began testing at medical institutions in Korea.

Early clinical trial results have shown that the Lunit INSIGHT data-driven imaging biomarker (DIB) technology raised diagnostic accuracy by 14 percent.


The technology analyzes existing X-ray images looking for major lung diseases, including lung cancer, pneumonia, pneumothorax and tuberculosis. Results can be generated a few seconds after the images are uploaded.

"Currently, DIB technology has achieved an accuracy level comparable to that of human experts," Anthony Paek, CEO of Lunit, said in a statement. "In the future, however, we will have new DIB technologies capable of outperforming humans."

In October, 2018, Vuno announced that it was beginning clinical trials at the Asan Medical Center of its cardiac arrest AI detection tool, DEWS, with plans, should final trials succeed, to make it commercially available in May of 2019.

DEWS can predict the onset of cardiac arrest symptoms 24 hours in advance using blood pressure, heart rate, respiratory rate, and temperature – along with deep learning technology.

Once the software is approved, it will be the world's first cardiac arrest prediction tool.

Back to HCB News

Business Affairs Homepage